Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

[Ergoline-induced retroperitoneal fibrosis].

Christoffersen CL, Siboni AH, Boisen E, Ladefoged C, Rasmussen C, Christensen-Dalsgaard S, Jakobsen P, Rasmussen LD, Schlander S.

Ugeskr Laeger. 2006 Apr 24;168(17):1667; author reply 1667. Danish. No abstract available.

PMID:
16674890
2.

PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.

Corbin AE, Meltzer LT, Ninteman FW, Wiley JN, Christoffersen CL, Wustrow DJ, Wise LD, Pugsley TA, Heffner TG.

Neuropharmacology. 2000 Apr 27;39(7):1211-21.

PMID:
10760363
3.
4.

The novel use of vascular access ports for intravenous self-administration and blood withdrawal studies in squirrel monkeys.

Kinsora JJ Jr, Christoffersen CL, Swalec JM, Juneau PL.

J Neurosci Methods. 1997 Jul 18;75(1):59-68.

PMID:
9262145
5.

Modulation of dopamine neuronal activity by glutamate receptor subtypes.

Meltzer LT, Christoffersen CL, Serpa KA.

Neurosci Biobehav Rev. 1997 Jul;21(4):511-8. Review.

PMID:
9195610
6.

Metabotropic glutamate receptor-mediated inhibition and excitation of substantia nigra dopamine neurons.

Meltzer LT, Serpa KA, Christoffersen CL.

Synapse. 1997 Jun;26(2):184-93.

PMID:
9131777
7.

Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys.

Feng MR, Corbin AE, Wang Y, Christoffersen CL, Wiley JN, Strenkoski CA, Tucker EV, Ninteman FW, Meltzer LT, Heffner TG, Wright DS.

Pharm Res. 1997 Mar;14(3):329-36.

PMID:
9098876
8.

CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.

Meltzer LT, Christoffersen CL, Corbin AE, Ninteman FW, Serpa KA, Wiley JN, Wise LD, Heffner TG.

J Pharmacol Exp Ther. 1995 Aug;274(2):912-20.

PMID:
7636754
10.

Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.

Meltzer LT, Caprathe BW, Christoffersen CL, Corbin AE, Jaen JC, Ninteman FW, Pugsley TA, Serpa KA, Shih YH, Whetzel SZ, et al.

J Pharmacol Exp Ther. 1993 Sep;266(3):1177-89.

PMID:
8103791
12.

Lack of involvement of haloperidol-sensitive sigma binding sites in modulation of dopamine neuronal activity and induction of dystonias by antipsychotic drugs.

Meltzer LT, Christoffersen CL, Serpa KA, Pugsley TA, Razmpour A, Heffner TG.

Neuropharmacology. 1992 Sep;31(9):961-7.

PMID:
1359446
13.

CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity.

Meltzer LT, Christoffersen CL, Heffner TG, Freeman AS, Chiodo LA.

J Pharmacol Exp Ther. 1989 Oct;251(1):123-30.

PMID:
2571714

Supplemental Content

Loading ...
Support Center